25价肺炎球菌结合疫苗在未接种成人中的安全性与免疫原性
两项在加拿大开展的随机、双盲、对照试验评估了单剂肌肉注射PCV25在无肺炎球菌疫苗接种史健康成人中的安全性和免疫原性,对照为PCV20。结果显示PCV25与PCV20的不良事件特征相似,最高剂量PCV25对全部25种血清型均诱导IgG和OPA应答,GMFR≥2(除OPA对35B外)。
要点
- PCV25与PCV20的不良事件特征相似,未报告4级事件。
- 最高剂量PCV25对全部25种血清型诱导IgG和OPA应答,GMFR≥2。
- 成人免疫原性不能完全预测婴儿,需在目标婴儿人群进一步评估。
核心结论
- PCV25多种配方在健康成人中耐受良好且具有免疫原性。
- 最高剂量PCV25对全部25种血清型诱导IgG和OPA应答,GMFR≥2(OPA对35B除外)。
研究设计与样本
- 两项在加拿大开展的随机、平行组、双盲临床试验。
- CVIA 096:每组30名受试者随机接受PCV25(2.2/125)或PCV20。
- CVIA105:40名随机接受PCV25(2.2/125),60名接受PCV25(2.2/250),80名接受PCV25(4.4/250),40名接受PCV20。
- 受试者为无肺炎球菌疫苗接种史或微生物学确诊IPD的健康成人。
主要发现
- 多数受试者为女性和白人。
- 所有受试者均纳入安全性分析;CVIA 096中1名和CVIA 105中6名受试者因可能干扰免疫应答的方案偏离被排除于免疫原性分析。
- PCV25与PCV20的征集性和非征集性不良事件特征相似。
- 未报告4级事件。
- 最高剂量PCV25对全部25种血清型诱导IgG和OPA应答,GMFR≥2;对6A血清型亦如此,但OPA对35B的应答除外。
临床怎么用
- PCV25在健康成人中耐受良好且具有免疫原性,支持进一步在目标婴儿人群中评估。
局限性
- 成人免疫原性不能完全预测婴儿免疫原性。
- 需在目标婴儿人群中进一步评估安全性和免疫原性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pneumococcus causes substantial morbidity and mortality worldwide in children under 5. IVT PCV-25 is a 25-valent pneumococcal conjugate vaccine (PCV25) designed to prevent invasive pneumococcal disease from the serotypes predominant in children, particularly in low and middle income countries (LMICs). METHODS: We completed 2 randomised, parallel-group, double-blind clinical trials in Canada to evaluate the safety and immunogenicity of a single IM dose of PCV25 in healthy adults who had no history of pneumococcal vaccination or microbiologically confirmed IPD. PCV20 (Prevnar 20) was the control. In CVIA 096, 30 participants per group were randomised to PCV25 at a dose similar to PCV 20 (2.2 μg for each serotype polysaccharide (except 4.4 μg for serotype 6B) with 125 μg aluminium as aluminium phosphate (2.2/125)) or PCV20. Potentially more immunogenic formulations with higher polysaccharide and/or aluminium phosphate dose were evaluated in CVIA105, where 40 participants were randomised to PCV25 (2.2/125), 60 to PCV25 (2.2/250), 80 to PCV25 (4.4/250), and 40 to PCV20. RESULTS: Most participants were female and white. All participants were included in the safety analyses. One participant in CVIA 096 and 6 participants in CVIA 105 were excluded from the immunogenicity analyses because of protocol deviations that might interfere with immune response. Solicited and unsolicited AE profiles were similar for PCV25 and PCV20. No Grade 4 events were reported. At the highest dose, PCV25 elicited IgG and OPA responses with GMFRs of ≥2 for all 25 serotypes and for serotype 6A except for OPA response to 35B. CONCLUSIONS: Multiple formulations of IVT PCV-25, a vaccine designed to cover pneumococcal serotypes prevalent in LMICs, were well tolerated and immunogenic in healthy adults. As adult immunogenicity is not fully predictive for infants, further development will evaluate safety and immunogenicity in the target infant population. CLINICALTRIALS: govNCT05540028,NCT06077656.
引用
- Langley JM, Sadarangani M, Ockenhouse C, et al. Safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive healthy adults: Results from 2 randomised, controlled clinical trials. Vaccine. 2026. PMID: 41576705. doi:10.1016/j.vaccine.2026.128236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。